Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Johnson and Johnson
Argus Health
Daiichi Sankyo
Covington
Baxter
Express Scripts
Mallinckrodt
Chinese Patent Office
Teva
UBS

Generated: August 23, 2017

DrugPatentWatch Database Preview

Theratechnologies Company Profile

« Back to Dashboard

What is the competitive landscape for THERATECHNOLOGIES, and when can generic versions of THERATECHNOLOGIES drugs launch?

THERATECHNOLOGIES has one approved drug.

There are three US patents protecting THERATECHNOLOGIES drugs.

There are forty-two patent family members on THERATECHNOLOGIES drugs in sixteen countries.

Summary for Applicant: Theratechnologies

Patents:3
Tradenames:1
Ingredients:1
NDAs:1
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Theratechnologies
EGRIFTA
tesamorelin acetate
POWDER;SUBCUTANEOUS022505-001Nov 10, 2010RXYesYes► Subscribe► Subscribe ► Subscribe
Theratechnologies
EGRIFTA
tesamorelin acetate
POWDER;SUBCUTANEOUS022505-001Nov 10, 2010RXYesYes► Subscribe► Subscribe ► Subscribe
Theratechnologies
EGRIFTA
tesamorelin acetate
POWDER;SUBCUTANEOUS022505-002Nov 29, 2011DISCNNoNo► Subscribe► Subscribe ► Subscribe
Theratechnologies
EGRIFTA
tesamorelin acetate
POWDER;SUBCUTANEOUS022505-001Nov 10, 2010RXYesYes► Subscribe► SubscribeYY ► Subscribe
Theratechnologies
EGRIFTA
tesamorelin acetate
POWDER;SUBCUTANEOUS022505-002Nov 29, 2011DISCNNoNo► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Theratechnologies

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Theratechnologies
EGRIFTA
tesamorelin acetate
POWDER;SUBCUTANEOUS022505-001Nov 10, 2010► Subscribe► Subscribe
Theratechnologies
EGRIFTA
tesamorelin acetate
POWDER;SUBCUTANEOUS022505-002Nov 29, 2011► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Theratechnologies

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,939,386 Chimeric fatty body-pro-GRF (1-29) analogs with increased biological potency► Subscribe
8,314,066GH secretagogues and uses thereof► Subscribe
6,458,764 GRF analogs with increased biological potency► Subscribe
8,481,489GH secretagogues and uses thereof► Subscribe
6,020,311 GRF analogs with increased biological potency► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Theratechnologies Drugs

Country Document Number Estimated Expiration
BrazilPI0516935► Subscribe
Canada2485472► Subscribe
World Intellectual Property Organization (WIPO)2006042408► Subscribe
World Intellectual Property Organization (WIPO)9637514► Subscribe
World Intellectual Property Organization (WIPO)0014236► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

McKinsey
US Department of Justice
Deloitte
Harvard Business School
Dow
McKesson
Cipla
Fish and Richardson
Medtronic
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot